Navigation Links
Novel monoclonal antibody offers potential treatment for tumors resistant to VEGF therapy
Date:11/13/2011

SAN FRANCISCO Despite the widespread use of current antiangiogenic cancer therapies, many tumors escape this blockade, which is designed to shut down growth of new blood vessels that feed tumors and spread cancer cells. Now, a study reported at the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics suggests that targeting a novel antiangiogenic receptor may help patients whose cancer does not respond to existing agents.

The experimental agent, PF-03446962, targets activin receptor-like kinase 1 (ALK-1), which is part of the transforming growth factor (TGF) superfamily of receptors that potentially regulate cell growth and differentiation. Known as a tumor suppressor, TGF can conversely promote invasion and metastasis during the later stages of cancer progression, said Filippo de Braud, M.D., who was director of new drugs at the European Institute of Oncology when the study was conducted and is now chief of the Medical Oncology Department at the National Tumor Institute in Milan, Italy.

Tumor cells frequently lose the growth inhibitory response to TGF, which makes it a prime target for cancer treatment, he said. PF-03446962, a fully humanized monoclonal antibody, specifically inhibits the activity of ALK-1, which the researchers said is in part regulated by vascular endothelial growth factor (VEGF), the protein that activates angiogenesis and other proangiogenic factors. Shutting down ALK-1 inhibits the VEGF pathway in a manner different from other antiangiogenic treatments now on the market, de Braud said.

Researchers tested PF-03446962 in a phase 1 clinical trial, which demonstrated that the agent exerted anticancer activity in tumors already resistant to VEGF treatment.

De Braud and his colleagues tested eight different doses of PF-03446962 in 44 patients with solid tumors. Results showed a partial response in three patients and stable disease lasting at least four months in seven patient
'/>"/>

Contact: Jeremy Moore
Jeremy.Moore@aacr.org
215-446-7109
American Association for Cancer Research
Source:Eurekalert

Page: 1 2

Related biology news :

1. Benefit of novel drug in breast cancer seen in blood within weeks
2. Novel technique switches triple-negative breast cancer cells to hormone-receptor positive cells
3. The Michael J. Fox Foundation awards nearly $200,000 to develop novel drugs for Parkinsons disease
4. Novel technique uses RNA interference to block inflammation
5. La Jolla Institute discovers novel mechanism for preventing infection via bodys mucosal borders
6. Novel drug combination offers therapeutic promise for hard-to-treat cancers
7. Novel approach scores first success against elusive cancer gene
8. Novel method for increasing antibiotic yields
9. Tropical coral could be used to create novel sunscreens for human use, say scientists
10. A novel mechanism that regulates pro-inflammatory cells is identified
11. Novel analysis by Allen Institute sheds new light on the mechanisms of brain development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... E. Fox, a John and Rebecca Moores Professor of Biology ... a fellow in the International Society for the Study of ... of four members two from the U.S., one from ... 2014. Fellows are elected every three years, and 36 have ... more than 20 countries, the ISSOL includes researchers from disciplines ...
(Date:8/20/2014)... 158 pregnant teenagers in Rochester, NY, nearly half engaged ... ice, cornstarch, vacuum dust, baby powder and soap, and ... Moreover, such teens had significantly lower iron levels as ... , Pregnant teens, regardless of pica, are at higher ... deficiency and anemia. Low iron in pregnant teens raises ...
(Date:8/20/2014)... LAKE CITY Researchers at Huntsman Cancer Institute (HCI) at ... forms of the gene that encodes BCR-ABL, the unregulated ... According to the American Cancer Society, nearly 6,000 new ... Drugs already in use, called tyrosine kinase inhibitors (TKIs), ... They do not cure CML but control it in ...
Breaking Biology News(10 mins):UH professor named fellow by International Astrobiology Society 2Pica in pregnant teens linked to low iron 2Blueprint for next generation of chronic myeloid leukemia treatment 2
... know Edward Teller as the "Father of the H-Bomb." To his ... detractors he was evil personified. Between these extremes was the life ... well researched attempt to interpret the enigmatic nature of a great ... beliefs," says G. A. Keyworth, II, science advisor to President Reagan, ...
... LAFAYETTE, Ind. - Greenhouse plant growers can substitute rice ... for an increase in growth regulators, according to a ... often consists of a soilless mix of peat and ... also regularly use plant-growth regulators to ensure consistent and ...
... Laxenburg, Austria 26th October 2010 --,A new assessment ... warming cautions that unless current imbalances in R&D portfolios ... technologies are redressed, greenhouse gas (GHG) emission reduction targets ... considerable costs. The study identifies energy efficiency as ...
Cached Biology News:'Judging Edward Teller' 2'Judging Edward Teller' 3Rice hulls a sustainable drainage option for greenhouse growers 2Changes in energy R&D needed to combat climate change 2Changes in energy R&D needed to combat climate change 3
(Date:8/21/2014)... 2014 OTC Markets Group Inc. ... biotechnology company, on its approval to list on ... OTCQX®, the best marketplace for established U.S. and ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... of its growth strategy and achievement of this ...
(Date:8/21/2014)... KONG , Aug. 21, 2014  China Cord Blood ... announced its plan to release financial results for the ... 28, 2014, after market close in the US.  ... at 8:00 a.m. ET on Friday, August 29, 2014 ... overview of the Company,s recent developments, followed by a ...
(Date:8/21/2014)... 2014  Four-dimensional (4-D) printing develops materials that ... stimuli such as changes in temperature. This advanced ... in multiple industries.  In the near future, 4-D ... objects ranging from human organs to parts used ... Logo - http://photos.prnewswire.com/prnh/20140820/138289 ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 Pursuit ... selling optimization technology and services for Life Sciences ... “Grading Pharma’s Use of New Commercial Sales Models” ... & Analytics. , The article examines some innovative ... that are being tested in the pharmaceutical market. ...
Breaking Biology Technology:OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2China Cord Blood Corporation to Report First Quarter of Fiscal 2015 Financial Results 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 2Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 3Frost & Sullivan: 4-D Printing to Usher in Age of Low-Labor, Fast-Paced Product Manufacturing 4Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2
... , ... Board: LTUS) ("Lotus" or the "Company") a growing developer ... pharmaceutical,products in the People,s Republic of China ("PRC"), today ... operating entity of Lotus,appointed Mr. Jinzhong HAN to be ...
... ... a multi-year, sole-source supply agreement with leading global dairy company Fonterra Co-operative Group Limited ... products for pregnant and nursing mothers. , ... Columbia, MD (Vocus) December 10, 2009 -- Martek Biosciences ...
... Collaboration to Create Optimized Antibodies Produces First Candidates Which ... Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. (NYSE YMI, ... program between YM and the National Research Council ... IntelliMab(TM) technology, the program is designed to generate novel ...
Cached Biology Technology:Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 2Lotus Pharmaceuticals, Inc. Appoints OTC Division Head 3Martek Signs Sole-Source Supply Agreement with Fonterra 2Martek Signs Sole-Source Supply Agreement with Fonterra 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 2YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 3YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 4YM BIOSCIENCES AND THE NATIONAL RESEARCH COUNCIL OF CANADA BIOTECHNOLOGY RESEARCH INSTITUTE (NRC-BRI) PRODUCE NEW BREAST CANCER DRUG CANDIDATES 5
...
Mouse Iduronate 2-Sulfatase Affinity Purified Polyclonal Ab Keywords: Sulfatases, Iduronate 2-Sulfatase, Mucopolysaccharidosis, Hunter Syndrome, Glycobiology Protein Family: Proteoglycan Regu...
Immunogen: Synthetic Peptide: C N(185) D G T E F G G S I Y Q K(197) Storage: -20 C, Avoid Freeze/Thaw Cycles...
... types of yeast two-hybrid studies, including complex interaction studies ... Choice of two bait vectors for maximum flexibility and ... Triple reporter strain NMY51 ensures an ... Complete set of controls: pLexA-p53, pLexA-lamin C and ...
Biology Products: